Sana Competitors
| SANA Stock | USD 3.85 0.06 1.58% |
Sana Biotechnology vs Oculis Holding Correlation
Average diversification
The correlation between Sana Biotechnology and OCS is 0.15 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sana Biotechnology and OCS in the same portfolio, assuming nothing else is changed.
Moving against Sana Stock
As of February 15, 2026, Return On Tangible Assets is expected to decline to -1.07. In addition to that, Return On Capital Employed is expected to decline to -0.72. At present, Sana Biotechnology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 361.6 M, whereas Non Current Assets Total are forecasted to decline to about 355.2 M.Sana Biotechnology Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sana Biotechnology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Sana and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sana Biotechnology does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Sana Stock performing well and Sana Biotechnology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sana Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NRIX | 3.19 | 0.41 | 0.11 | 0.59 | 3.13 | 7.07 | 27.63 | |||
| INBX | 3.09 | (0.01) | (0.01) | 0.00 | 4.08 | 5.86 | 17.82 | |||
| NKTR | 4.64 | 0.54 | 0.10 | 0.99 | 4.83 | 8.03 | 44.06 | |||
| SNDX | 2.57 | 0.39 | 0.17 | 0.45 | 2.06 | 5.69 | 18.37 | |||
| DNTH | 2.97 | 0.46 | 0.13 | 1.91 | 2.82 | 8.95 | 23.32 | |||
| KOD | 4.04 | 0.27 | 0.07 | 0.21 | 3.97 | 9.66 | 23.68 | |||
| PHAT | 2.82 | (0.16) | 0.00 | (0.44) | 0.00 | 5.99 | 24.16 | |||
| XNCR | 2.74 | (0.34) | 0.00 | (1.33) | 0.00 | 6.33 | 16.84 | |||
| RLAY | 3.18 | 0.59 | 0.17 | 0.69 | 3.14 | 6.40 | 30.68 | |||
| OCS | 1.98 | 0.60 | 0.24 | 2.31 | 1.71 | 5.79 | 16.37 |
Cross Equities Net Income Analysis
Compare Sana Biotechnology and related stocks such as Nurix Therapeutics, Inhibrx Biosciences, and Nektar Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRIX | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (21.7 M) | (43.2 M) | (117.2 M) | (166 M) | (143.9 M) | (193.6 M) | (264.5 M) | (238 M) | (226.1 M) |
| INBX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (19.4 M) | (31.2 M) | (51.4 M) | (75.6 M) | (81.8 M) | (145.2 M) | (241.4 M) | 1.7 B | 1.9 B | 2 B |
| NKTR | (5.3 M) | (134 M) | (171.9 M) | (162 M) | (53.9 M) | (81.2 M) | (153.5 M) | (96.7 M) | 681.3 M | (440.7 M) | (444.4 M) | (523.8 M) | (368.2 M) | (276.1 M) | (119 M) | (107.1 M) | (112.4 M) |
| SNDX | (13.1 M) | (13.1 M) | (10 M) | (14.2 M) | (19.8 M) | (24.1 M) | (44.5 M) | (60.8 M) | (74 M) | (56 M) | (73.1 M) | 24.9 M | (143.7 M) | (209.4 M) | (318.8 M) | (286.9 M) | (272.5 M) |
| DNTH | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (35.5 M) | (57.5 M) | (76.8 M) | (74.9 M) | (13.1 M) | (28.5 M) | (43.6 M) | (85 M) | (76.5 M) | (72.6 M) |
| KOD | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (27.9 M) | (41.4 M) | (47.4 M) | (133.1 M) | (267 M) | (333.8 M) | (260.5 M) | (176.2 M) | (158.6 M) | (166.5 M) |
| PHAT | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (209.7 M) | (129.1 M) | (143.9 M) | (197.7 M) | (201.6 M) | (334.3 M) | (300.9 M) | (285.8 M) |
| XNCR | (11.2 M) | (11.2 M) | (8.6 M) | (60.3 M) | (16.4 M) | (17.6 M) | 23.6 M | (48.9 M) | (70.4 M) | 26.9 M | (63.5 M) | 82.6 M | (55.2 M) | (126.1 M) | (232.6 M) | (209.4 M) | (198.9 M) |
| RLAY | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (66.5 M) | (52.4 M) | (363.9 M) | (290.5 M) | (342 M) | (337.7 M) | (303.9 M) | (319.1 M) |
| OCS | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (18.6 M) | (38.7 M) | (88.8 M) | (85.8 M) | (77.2 M) | (81.1 M) |
Sana Biotechnology and related stocks such as Nurix Therapeutics, Inhibrx Biosciences, and Nektar Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Sana Biotechnology financial statement analysis. It represents the amount of money remaining after all of Sana Biotechnology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Sana Biotechnology Competitive Analysis
The better you understand Sana Biotechnology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sana Biotechnology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sana Biotechnology's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Sana Biotechnology Competition Performance Charts
Five steps to successful analysis of Sana Biotechnology Competition
Sana Biotechnology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sana Biotechnology in relation to its competition. Sana Biotechnology's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Sana Biotechnology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sana Biotechnology's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sana Biotechnology, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Sana Biotechnology position
In addition to having Sana Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Computers Thematic Idea Now
Computers
Companies that manufacture and distribute personal and business computers. The Computers theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Computers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sana Biotechnology Correlation with its peers. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Sana Biotechnology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Sana Biotechnology requires distinguishing between market price and book value, where the latter reflects Sana's accounting equity. The concept of intrinsic value - what Sana Biotechnology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Sana Biotechnology's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sana Biotechnology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.